Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. September 2019 07:00 ET | Quelle: Imvax, Inc.

Imvax Appoints John P. Furey as Chief Executive Officer

PHILADELPHIA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a discovery and clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy...
31. März 2019 15:00 ET | Quelle: Imvax, Inc.

Imvax Announces Positive Results from Clinical Trial of Novel IGV-001 Autologous Cell Vaccine in Treating Patients with Newly Diagnosed Glioblastoma

Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months in published standard of care studies Median progression-free survival was 10.4 months vs. 6.9 and 5.4 months in...
27. März 2019 08:00 ET | Quelle: Imvax, Inc.

Imvax to Present Results from Phase 1b Clinical Trial of IGV-001 in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2019

PHILADELPHIA, March 27, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies,...